Oryzon Genomics Announces First Patient Dosed in Phase I Extension Cohort of ORY-1001
Extension cohort (Part 2) of the current Phase I clinical trial to assess the efficacy of ORY-1001 in patients with acute myeloid leukemia in 10 centers in Spain, UK and France
BARCELONA, SPAIN and CAMBRIDGE MA
Oryzon Genomics, a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced today the dosing of the first patient in the extension cohort (Part 2) of its ORY-1001 Phase I clinical trial.